Ileostomy Clinical Trial
Official title:
Zinc and Copper Absorption in Neonates With Bilious Losses
We propose to examine the absorption and excretion of zinc and copper in infants with
ostomies. This will be accomplished by measuring baseline excretion and serum levels of
zinc, copper, and ceruloplasmin, and by utilizing stable isotopes of zinc and copper to
measure absorption and excretion.
To determine how the presence of an ileostomy impacts zinc and copper metabolism in infants
at three time points: 1) when the infant has an ostomy and is receiving the majority of
calories from total parenteral nutrition (TPN); 2) when the infant has an ostomy and is
receiving primarily enteral nutrition without TPN; and 3) when/if the infant has a surgery
to reconnect the bowel and is receiving primarily enteral nutrition.
For the first part of the study, excretion data for zinc will be obtained for ostomy
patients. We hypothesize that infants with an ostomy will excrete more zinc in their stools
than healthy term or preterm infants without ostomies.
For the second part of the study, we will obtain data on zinc absorption, secretion, and
excretion through use of stable isotopes. Jalla et al determined that healthy infants retain
zinc of 0.4 mg/day. We hypothesize that due to increased zinc losses, the infants in the
study will be less positive than the healthy infants in the study by Jalla et al. Our study
is designed to be able to detect if the ostomy patients net retention is one-half that
described by Jalla (i.e. 0.2 mg/d). We will also obtain data on copper absorption,
secretion, and excretion through the use of stable isotopes in the second part of the study.
As a pilot study, we do not fully know what to expect regarding copper levels in infants
with ostomies, but we hypothesize that they may be less positive than healthy infants
without ostomies. Also, we hypothesize that zinc and copper are competitively absorbed in
the gut; therefore, infants who receive more zinc may absorb less copper.
For the third part of the study, we will obtain data on zinc absorption through the use of
stable isotopes after the infant has had surgery to reanastomose the bowel. We hypothesize
that there may be continued zinc losses above those documented for healthy infants who have
never had an ostomy, but decreased losses compared to when the infant had an ostomy.
Potential subjects will be identified by study personnel in the Neonatal Intensive Care
Units (NICU) of Texas Children's Hospital and Ben Taub General Hospital. The parent/guardian
will be approached and the study will be explained in full. A time for questions will be
allowed. Once the parent/guardian agrees to his/her child's participation, an informed
written consent form will be signed. Subject confidentiality will be maintained within the
limits of the law. All names and personal information will be accessed only by the
investigators and authorized personnel. There will be no possibility of coercion as subjects
will not have any relationship of dependency with the investigators.
We intend to asses zinc and copper metabolism at three time points: first, when the infant
has an ostomy and is receiving primarily intravenous nutrition, called total parenteral
nutrition (TPN), with minimal or no enteral feeds (ie, feeds into the gastrointestinal
tract); second, when the infant has an ostomy and is receiving primarily enteral nutrition
without TPN; and third, when/if the infant has a surgery to reconnect the bowel and remove
the ostomy. Using stable isotope techniques for the second and third parts, we will measure
intake compared to excretions (stool in ostomy and urine). A stable isotope is naturally
occurring form of a mineral that we can measure, or trace, in the body. It is not
radioactive and there are no known risks from it.
Part 1: This part will not include any stable isotopes. We will collect the ostomy and urine
output for 24 hours to determine the zinc and copper content of the ostomy output and the
urine. A small collection of blood (2 mL) will also be obtained at the same time other
routine blood tests are being done. This blood will be tested for zinc, copper, and
ceruloplasmin levels. If the infant has a replogle or other gastric tube, gastric residuals
will be collected during the same 24 hours that stool from the ostomy is collected. If for
some reason Part 1 is not able to be performed before the subject meets the criteria for
Part 2, the subject will not be dropped. Part 1 will be considered optional. The following
will be measured: zinc intake (from the zinc content of the TPN), endogenous fecal excretion
(from the ostomy and gastric outputs) and urinary zinc excretion (from the urine
collection). Zinc balance will be estimated from the difference in zinc intake and zinc
output (in the ostomy, urine, and gastric fluid). Copper balance will be measured from the
difference in copper intake (in TPN) and copper losses (in the ostomy, urine and gastric
fluid).
Part 2: The second part of the study will occur when the infant has reached full enteral
feedings (minimum of 100 cc/kg/day) and TPN has been discontinued. This part of the study
will include stable isotopes. Infants should be receiving a steady state volume and
concentration of feedings per kg for at least two (2) days and throughout the first 24 hours
of the sample collection period. The time recorded that the infant receives the first
isotope will mark the beginning of the sample collection period. Infants may be receiving
either breast milk (fortified or unfortified) or infant formula. If the infant is receiving
breast milk, a 10mL sample of breast milk will be obtained to determine zinc and copper
content. Zinc and copper contents of infant formula will be determined from published tables
by the manufacturer. The infant will receive 1 mg Zn67 and 80 mcg Cu65 stable isotope orally
mixed into one of the infant's morning feedings on the study day. In addition, the infant
will receive 0.1 mg Zn70 intravenous stable isotope. Stool will be collected from the ostomy
bag for 72 hours. A urine bag will be placed on the infant's skin to collect all the urine
for 24 hours, followed by a spot urine sample collection twice a day for three (3) days
after the isotope infusion. The final urine collection should occur at approximately 96
hours after the isotope infusion. A small amount of blood (2 mL) will also be taken at the
time of the intravenous isotope infusion. This blood will be tested for zinc, copper, and
ceruloplasmin levels. Fractional zinc absorption and endogenous fecal zinc excretion will be
measured using stable isotopes. Urinary excretion will be measured from the urine
collection. Zinc balance will be calculated from the difference in absorbed zinc (intake x
fractional absorption) and zinc losses (urinary excretion and endogenous fecal zinc
excretion). Fractional copper absorption will be measured from the difference in intake of
Cu65 and the losses of Cu65 (in the ostomy and urine). Copper balance will be measured from
the difference in total copper intake and total copper losses (in the ostomy and urine).
Part 3: The third part of the study will occur after the infant has a surgery to reconnect
the bowel and remove the ostomy. A spot urine sample will be obtained prior to the stable
isotope infusion to ensure that isotope previously consumed/infused will not be considered
in the data analysis for this part of the study. The stable isotope study will occur
whenever the infant's bowel has been reconnected and the infant has achieved a steady volume
and concentration of feedings per kg (minimum of 100 cc/kg/day) for at least 2 days. This
volume will continue throughout the first 24 hours of the sample collection period. Infants
may be receiving either breast milk (fortified or unfortified) or infant formula. If the
infant is receiving breast milk, a 10mL sample of breast milk will be obtained to determine
zinc and copper content. Zinc and copper contents of infant formula will be determined from
published tables by the manufacturer.
As the ostomy bag has been removed, it will be difficult to obtain stool samples for 72
hours. Therefore, we will only measure zinc urine excretion, not secretion and will not be
able to assess copper balance at this time point. The infant will receive 1 mg Zn67 orally
mixed into one of the infant's morning feedings on the study day. In addition, the infant
will receive 0.1 mg Zn70 intravenously. A small collection of blood (2 mL) will also be
taken at the time of the isotope infusion. This blood will be tested for zinc, copper, and
ceruloplasmin levels. One spot urine sample will be obtained at 96 hours after the first
isotope is received.
Study-related information will be recorded from the medical record and will include type and
volume of enteral feedings, volume and concentrations of TPN, anthropometrics,
nutrition-related lab results from routine blood draws (ie, BUN, creatinine, electrolytes,
bilirubin, calcium, phosphorus, alkaline phosphatase, and triglycerides), and ostomy and
urine output.
Recognizing that there is the possibility that not every infant will have a surgery to
reconnect the bowel, the consent form will clearly state that their child may or may not be
eligible for Part 3.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01514136 -
An Investigation of Ostomy Devices
|
N/A | |
Terminated |
NCT04372992 -
The Stoma Closure Before or After Adjuvant Therapy Trial
|
N/A | |
Completed |
NCT02594085 -
An Exploratory Study Investigating Adhesive Reaction to Output
|
N/A | |
Completed |
NCT02543190 -
System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program
|
N/A | |
Terminated |
NCT01782196 -
A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy
|
N/A | |
Completed |
NCT02610907 -
A Pilot Evaluation of Adhesives and How They Are Impacted by Out-put
|
N/A | |
Completed |
NCT02626260 -
A Pilot Evaluation of Adhesives and How They Are Impacted by Output
|
N/A | |
Completed |
NCT00428636 -
Early Temporary Stoma Closure After Proctectomy
|
N/A | |
Completed |
NCT03909542 -
Malnutrition Associated With Complications After Ileostomy Reversal
|
||
Recruiting |
NCT02499588 -
User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technologyâ„¢
|
N/A | |
Completed |
NCT01939106 -
One Piece Drainable Pouch in Subjects With an Ileostomy
|
Phase 2 | |
Completed |
NCT00128804 -
The STOVITA Study - Bioefficacy of Beta-Carotene in Oil and in a Mixed Diet in Ileostomy Patients
|
N/A | |
Completed |
NCT02675634 -
Investigation of Two New 1-piece Ostomy Products in People With an Ileostomy or Colostomy
|
N/A | |
Terminated |
NCT02042677 -
Assessment of a Skin Barrier
|
N/A | |
Completed |
NCT05915052 -
B-suture Ileostomy in Clinical Practice: a Retrospective, Single-center, Propensity Score-matched Study
|
N/A | |
Completed |
NCT02351817 -
An Explorative Randomized Controlled Investigation Evaluating Newly Developed Ostomy Products
|
N/A | |
Completed |
NCT02351791 -
An Exploratory Study Investigating Human Skin Reaction to Output
|
N/A | |
Completed |
NCT02362360 -
Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy
|
N/A | |
Recruiting |
NCT05457660 -
Transverse Study About QOL for Colostomized or Ileostomized Patients During Their Home Hospitalization
|
||
Completed |
NCT02036346 -
Electrolyte Profile, Nutritional Status and Ileostomy Formation.
|
N/A |